Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Aims and methods: The aim of this monocentric retrospective observational study was to evaluate the 18-month safety and effectiveness of GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) 1.5 mg/once weekly as an add-on to metformin (MET) or MET plus conventional insulin secretagogues in a study coh...

Full description

Bibliographic Details
Main Authors:	Maria Mirabelli, Eusebio Chiefari, Vera Tocci, Patrizia Caroleo, Stefania Giuliano, Emanuela Greco, Raul Miguel Luque, Luigi Puccio, Daniela Patrizia Foti, Antonio Aversa, Antonio Brunetti
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Journal of Clinical Medicine
Subjects:	GLP-1 receptor agonist (GLP-1 RA) dulaglutide liraglutide add-on therapy type 2 diabetes obesity
Online Access:	https://www.mdpi.com/2077-0383/10/5/985

Similar Items

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Exacerbation of atrial fibrillation related to dulaglutide use
by: Jayden Lee, et al.
Published: (2021-05-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
by: Hisayuki Katsuyama, et al.
Published: (2023-03-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
by: Daiji Kawanami, et al.
Published: (2020-06-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide
by: Toshitaka Sawamura, et al.
Published: (2022-02-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2021-01-01)

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature
by: Benedetta Sonego, et al.
Published: (2023-06-01)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
by: S. Ghosal, et al.
Published: (2018-05-01)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
by: Kai-Cheng Chang, et al.
Published: (2020-10-01)

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
by: Samuel J. P. Malkin, et al.
Published: (2022-02-01)

Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
by: Angela Dardano, et al.
Published: (2022-02-01)

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
by: Hwi Seung Kim, et al.
Published: (2022-10-01)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
by: Mihaela-Simona Popoviciu, et al.
Published: (2023-06-01)

Editorial: Incretin agonists in the treatment of obesity
by: Xiaodong Sun, et al.
Published: (2023-08-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
by: Christoffer Clemmensen, et al.
Published: (2015-03-01)

Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
by: Paolo Basile, et al.
Published: (2023-02-01)

The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
by: Agata Juda, et al.
Published: (2022-11-01)

Liraglutide ameliorates diabetic-induced testicular dysfunction in male rats: role of GLP-1/Kiss1/GnRH and TGF-β/Smad signaling pathways
by: Maha Abdelhamid Fathy, et al.
Published: (2023-07-01)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
by: Junpei Sanada, et al.
Published: (2021-08-01)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022-07-01)

Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation
by: O. K. Vikulova, et al.
Published: (2022-03-01)

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
by: Juan Pang, et al.
Published: (2022-11-01)

The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
by: Aldawsari M, et al.
Published: (2023-03-01)

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
by: Natia Peradze, et al.
Published: (2019-10-01)

The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway
by: Yi Bao, et al.
Published: (2015-07-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies
by: Guizhen Chang, et al.
Published: (2022-04-01)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
by: Ying Liu, et al.
Published: (2017-12-01)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
by: Juan Du, et al.
Published: (2023-01-01)

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
by: Chia Siang Kow, et al.
Published: (2023-09-01)